MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback